5yzd
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='5yzd' size='340' side='right' caption='[[5yzd]], [[Resolution|resolution]] 2.64Å' scene=''> | <StructureSection load='5yzd' size='340' side='right' caption='[[5yzd]], [[Resolution|resolution]] 2.64Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[5yzd]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5YZD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5YZD FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5yzd]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Measc Measc]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5YZD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5YZD FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DPN:D-PHENYLALANINE'>DPN</scene>, <scene name='pdbligand=PHQ:BENZYL+CHLOROCARBONATE'>PHQ</scene></td></tr> | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DPN:D-PHENYLALANINE'>DPN</scene>, <scene name='pdbligand=PHQ:BENZYL+CHLOROCARBONATE'>PHQ</scene></td></tr> | ||
Line 9: | Line 9: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yzd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yzd OCA], [http://pdbe.org/5yzd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yzd RCSB], [http://www.ebi.ac.uk/pdbsum/5yzd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yzd ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yzd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yzd OCA], [http://pdbe.org/5yzd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yzd RCSB], [http://www.ebi.ac.uk/pdbsum/5yzd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yzd ProSAT]</span></td></tr> | ||
</table> | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Measles virus (MeV), a major cause of childhood morbidity and mortality, is highly immunotropic and one of the most contagious pathogens. MeV may establish, albeit rarely, persistent infection in the central nervous system, causing fatal and intractable neurodegenerative diseases such as subacute sclerosing panencephalitis and measles inclusion body encephalitis. Recent studies have suggested that particular substitutions in the MeV fusion (F) protein are involved in the pathogenesis by destabilizing the F protein and endowing it with hyperfusogenicity. Here we show the crystal structures of the prefusion MeV-F alone and in complex with the small compound AS-48 or a fusion inhibitor peptide. Notably, these independently developed inhibitors bind the same hydrophobic pocket located at the region connecting the head and stalk of MeV-F, where a number of substitutions in MeV isolates from neurodegenerative diseases are also localized. Since these inhibitors could suppress membrane fusion mediated by most of the hyperfusogenic MeV-F mutants, the development of more effective inhibitors based on the structures may be warranted to treat MeV-induced neurodegenerative diseases. | ||
+ | |||
+ | Structures of the prefusion form of measles virus fusion protein in complex with inhibitors.,Hashiguchi T, Fukuda Y, Matsuoka R, Kuroda D, Kubota M, Shirogane Y, Watanabe S, Tsumoto K, Kohda D, Plemper RK, Yanagi Y Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2496-2501. doi:, 10.1073/pnas.1718957115. Epub 2018 Feb 20. PMID:29463726<ref>PMID:29463726</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 5yzd" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Measc]] | ||
[[Category: Fukuda, Y]] | [[Category: Fukuda, Y]] | ||
[[Category: Hashiguchi, T]] | [[Category: Hashiguchi, T]] |
Revision as of 06:19, 8 March 2018
Crystal structure of the prefusion form of measles virus fusion protein in complex with a fusion inhibitor peptide (FIP)
|